Lupin acquires Dutch firm Nanomi to enter complex injectables market

Lupin Limited has acquired Dutch firm Nanomi B.V, marking its foray into the technology intensive complex injectables space. Nanomi, which has patented technology platforms to develop complex injectable products, has a rich talent pool of scientists who would be backed by Lupin’s global R&D and manufacturing teams.
 
Vinita Gupta, Chief Executive Officer, Lupin Limited, said “We are very pleased with the acquisition of Nanomi. With the use of Nanomi’s proprietary technology platform, Lupin would be able to make significant in?roads into the niche area of complex injectables.”
 
Founded in 2004, Nanomi is an independent, privately owned Dutch drug delivery company that develops pharmaceutical products based on nano- and microparticles. The proprietary and versatile microfluidic Monosphere Technology brings the precision of the semiconductor industry to the life sciences, enabling the manufacturing of uniform custom-made particles for pharmaceutical but also life sciences specialty products in a robust, reproducible and cost effective way, from laboratory to commercial scale.